A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Launched by GENENTECH, INC. · Jun 24, 2020
Trial Information
Current as of September 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new treatment called GDC-6036 for patients with advanced or metastatic solid tumors that have a specific mutation known as KRAS G12C. The trial aims to understand how safe this treatment is, how the body processes it, and whether it shows any signs of effectiveness. Patients eligible to join the study must have a confirmed diagnosis of a solid tumor with the KRAS G12C mutation and meet specific health requirements, such as avoiding certain conditions that could complicate treatment.
Participants in the trial can expect to receive GDC-6036 either on its own or in combination with other treatments, depending on the study design. The research team will closely monitor their health and response to the medication throughout the study. It's important for potential participants to know that women of childbearing age need to take precautions to avoid pregnancy, and men must also take measures to prevent fathering a child during the trial. This study is currently looking for volunteers, so if you or someone you know may qualify, it could be an opportunity to contribute to important cancer research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
- • Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.
- • Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.
- Exclusion Criteria:
- • Active brain metastases.
- • Malabsorption or other condition that interferes with enteral absorption.
- • Clinically significant cardiovascular dysfunction or liver disease.
About Genentech, Inc.
Genentech, Inc. is a leading biotechnology company and a member of the Roche Group, dedicated to transforming the lives of patients with serious medical conditions through innovative therapies. Established in 1976, Genentech is recognized for its pioneering research in biologics and for developing groundbreaking treatments in areas such as oncology, immunology, and neuroscience. With a commitment to scientific excellence and patient-centered care, the company leverages cutting-edge technology and collaborative partnerships to advance drug discovery and development. Genentech's robust pipeline and focus on personalized medicine underscore its mission to address unmet medical needs and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Duarte, California, United States
New York, New York, United States
Valencia, Spain
Boston, Massachusetts, United States
Oklahoma City, Oklahoma, United States
Seoul, Korea, Republic Of
Birmingham, United Kingdom
Basel, Switzerland
Montreal, Quebec, Canada
Curitiba, Brazil
Malaga, Spain
New Haven, Connecticut, United States
Ottawa, Ontario, Canada
Auckland, New Zealand
Pittsburgh, Pennsylvania, United States
Edegem, Belgium
Auckland, New Zealand
La Jolla, California, United States
Sevilla, Spain
Philadelphia, Pennsylvania, United States
Barcelona, Spain
Bern, Switzerland
Manchester, United Kingdom
Seoul, Korea, Republic Of
Sao Paulo, Sp, Brazil
Barretos, Sp, Brazil
Madrid, Spain
Utrecht, Netherlands
Cardiff, United Kingdom
Gdansk, Poland
Budapest, Hungary
San Francisco, California, United States
North Melbourne, Victoria, Australia
Toronto, Ontario, Canada
Liège, Belgium
Budapest, Hungary
Maastricht, Netherlands
Darlinghurst, New South Wales, Australia
Basel, Switzerland
Leiden, Netherlands
Curitiba, Paraná, Brazil
Genève, Switzerland
Birmingham, United Kingdom
Seongnam Si, Gyeonggi Do, Korea, Republic Of
Milano, Lombardia, Italy
Dresden, Germany
Milano, Italy
Philadelphia, Pennsylvania, United States
Sarasota, Florida, United States
London, United Kingdom
Oklahoma City, Oklahoma, United States
Melbourne, Victoria, Australia
Bergen, Norway
Haifa, Israel
Nedlands, Western Australia, Australia
Tel Aviv, Israel
Curitiba, Pr, Brazil
Pisa, Toscana, Italy
Seoul, Korea, Republic Of
Seoul, Korea, Republic Of
Pisa, Toscana, Italy
New Haven, Connecticut, United States
Rozzano (Mi), Lombardia, Italy
Amsterdam, Netherlands
Melbourne, Victoria, Australia
Porto Alegre, Rio Grande Do Sul, Brazil
Madrid, Spain
Orange, California, United States
Madrid, Spain
Kazan, Tatarstan, Russian Federation
Milano, Lombardia, Italy
Mechelen, Belgium
Poznań, Poland
London, United Kingdom
Auckland, New Zealand
Herstal, Belgium
Ramat Gan, Israel
Meldola, Emilia Romagna, Italy
Nairobi, Kenya
Montreal, Quebec, Canada
Ramat Gan, Israel
Christchurch, New Zealand
Oslo, Norway
Jozefow, Poland
Zürich, Switzerland
Nairobi, Kenya
Sao Jose Do Rio Preto, Sp, Brazil
Porto Alegre, Pa, Brazil
Christchurch, New Zealand
Bergen, Norway
Belo Horizonte, Mg, Brazil
Porto Alegre, Rs, Brazil
Budapest, Hungary
New York, New York, United States
Caxias Do Sul, Rs, Brazil
Rio De Janeiro, Rj, Brazil
Pozna?, Poland
Gyongyos, Hungary
Mount Kuring Gai, New South Wales, Australia
Porto Alegre, Pa, Brazil
Belo Horizonte, Mg, Brazil
Ramat Gan, Israel
Budapest, Hungary
Sao Paulo, Brazil
Gyöngyös, Hungary
Sao Paulo, São Paulo, Brazil
Barretos, São Paulo, Brazil
Sao Jose Do Rio Preto, São Paulo, Brazil
San Francisco, California, United States
Belo Horizonte, Minas Gerais, Brazil
Porto Alegre, Pará, Brazil
Caxias Do Sul, Rio Grande Do Sul, Brazil
Rio De Janeiro, Brazil
Gdansk, Poland
Barretos, Brazil
Porto Alegre, Brazil
Sao Jose Do Rio Preto, Brazil
Patients applied
Trial Officials
Clinical Trials
Study Director
Genentech, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials